跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2023/12/060430
CTRI/2023/12/060430尚未招募2 期

An Open-Label, Multicenter, Randomized, Two-Treatment, Two-Periods, Two-Sequence, Comparative pharmacokinetic and Effectiveness Study of WD- 1905 Tablets with SINEMET® (carbidopa and levodopa) Tablets in Parkinsons Disease (PD) Subjects with Morning Akinesia. - NI

Shanghai WD Pharmaceutical Co., Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
2 期
状态
尚未招募
发起方
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •1. Male or non-pregnant, non-lactating female between = 30 and = 75 years of age.
  • •2. Clinical diagnosis of idiopathic PD consistent with the UK PD Brain Bank Society.
  • •3. Clinically meaningful response to levodopa.
  • •4. Receiving stable daily doses of levodopa =450 mg and =1500 mg divided to at least three times a day during daytime at least 4 weeks before study participation.
  • •5. May be receiving other concomitant anti-PD medications except for non-selective Mono Amino Oxidase (MAO) inhibitors (must be discontinued for at least 30 days prior to screening).
  • •6. Well-defined early morning OFF ? (morning akinesia) persists at least 3 weeks as recorded by subject’s diary and determined by the Investigator before study drug administration.
  • •7. Experience predictable OFF episodes in early morning on awakening prior to receiving morning dose of levodopa.
  • •8. Total duration of = 3 hours’ OFF-time each day, based on the OFF-time diary (Hauser Diary/patient motor diary) collected over 3 consecutive days (Day-3 to Day -1) during the screening period.
  • •9. Stage 4 or less on the Hoehn and Yahr scale in the ON state.
  • •10. Mini Mental State Examination (MMSE) = 25 as assessed by Investigator during screening.
  • •11. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study related procedures to complete the study.
  • •12. Male or female of childbearing potential willing to use adequate methods of contraception throughout the study
  • •13. Subject/LAR able to understand the consent form, and to provide written informed consent.

排除标准

  • •Exclusion Criteria:
  • •1. Known hypersensitivity to levodopa or carbidopa.
  • •2. Atypical or secondary Parkinsonism.
  • •3. History of intracranial surgical intervention for PD or other indications (pallidotomy, thalamotomy, deep brain stimulation, etc).
  • •4. Changes in levodopa or other PD drug dosing regimens 4 weeks before the screening visit.
  • •5. Any history of sleep attacks, impulse control issues, or hypersexuality.
  • •6. Subject has undergone neurosurgery for the treatment of PD.
  • •7. Subject has any neurological deficit that might interfere with the study assessments (e.g., hemiparesis).
  • •8. Subject has contraindications to levodopa, (e.g., narrow angle glaucoma, malignant melanoma).
  • •9. Participation in any other clinical trial within 30 days of the screening visit or administration of an investigational product in another trial within 30 days or 5 half-lives (whichever is longer) prior to the screening visit.
  • •10. Drug or alcohol dependency in the past 6 months.
  • •11. Presence of significant orthostatic hypotension (i.e., decrease in systolic blood pressure =20 mmHg or diastolic BP of =10 mmHg when comparing standing to supine values within 3 minutes).
  • •12. A history of gastric surgery, including bariatric surgery within the past year.
  • •13. A positive screen for hepatitis (includes subtypes B & C) or HIV antibody.
  • •14. Malignant melanoma or a history of previously treated malignant melanoma within 5 years.
  • •15. Clinically significant medical, surgical or laboratory abnormality in the judgment of the Investigator.
  • •16. History of suicidal ideation or attempted suicide within the previous 12 months.
  • •17. Psychiatric disorder, including but not limited to dementia or any disorder that, in the opinion of the Investigator requires ongoing treatment that would make study participation unsafe or make treatment compliance difficult.
  • •18. Severe dyskinesia (defined as per MDS-UPDRS Part-III) that would significantly interfere with the subjects ability to perform study assessments.
  • •19. Consumption of grapefruit, grapefruit-like or grapefruit containing products within 7 days prior to initial drug administration throughout the study duration.
  • •20. Ingestion of any alcoholic, caffeine or xanthine containing food or beverage for at least 48 hours prior to the initial dose of study medication to throughout the study duration.
  • •21. Use of any drugs affecting the Absorption, Distribution, Metabolism and Excretion (ADME) of levodopa and carbidopa within 30 days prior to receiving the first dose of study medication. They can be allowed depending on Principal Investigator’s discretion in consultation with medical monitor if they are kept constant in the last 30 days and are expected to remain constant during the study period.
  • •22. Donation or loss of blood or plasma of one unit (about 450 mL whole blood or 220 mL plasma) in the previous 90 days prior to screening.
  • •23. History of difficulty with donating blood or difficulty in accessibility of veins or intolerance to venipuncture.
  • •24. History of difficulty in swallowing of study medication, or any other gastrointestinal disease, which could affect drug absorption.
  • •25. Laboratory test abnormalities at screening (Visit 1) deemed clinically significant judged by the Investigator.
  • •26. Any other condition that, in the Investigator’s judgment, might increa

研究者

发起方
Shanghai WD Pharmaceutical Co., Ltd.

相似试验

进行中（未招募）
Unknown
To assess the bioequivalence and safety of paliperidone 100mg prolonged release suspension for injection of Sun Pharmaceutical Industries Ltd, India in schizophrenic patients
CTRI/2023/09/058099Sun Pharmaceutical Industries Limited,
已完成
不适用
Bio equivalent study of Methotrexate tablet 2.5 mg of Eugia Pharma specialites Limited, India with Methotrexate tablets 2.5 mg of Dava Pharmaceuticals Inc, USA in adult patients with mild to severe Psoriasis or Rheumatoid Arthritis
CTRI/2016/08/007152Eugia Pharma Specialities Limited A JV of Aurobindo Pharma Limited Celon Laboratories Limited36
招募中
1 期
A Randomized, Open-Label, Multicenter, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection 2mg/mL (50 mg/m dose)
CTRI/2021/12/038914Alembic Pharmaceuticals Limited
进行中（未招募）
不适用
Bioequivalence (BE) Study of Pazopanib in subjects with Advanced renal cell carcinoma.
CTRI/2020/11/029079Alvogen PB RD LLC
尚未招募
不适用
A bioequivalance study comparing Tobradex eye drops of Alcon pharma with study medication with same combination of Cipla in aqueous humor of patients undergoing cataract surgery.
CTRI/2015/10/006326Cipla Ltd36